v3.26.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Current assets    
Cash and cash equivalents $ 3,110.8 $ 2,938.0
Short-term investments (Note 5) 1,533.9 1,288.3
Accounts receivable, net of allowances of $17.0 and $15.0, respectively 784.9 659.6
Other receivables 152.9 252.5
Inventories (Note 2) 1,159.4 1,126.2
Prepaid expenses 147.2 135.0
Other current assets 358.4 339.3
Total current assets 7,247.5 6,738.9
Long-term investments (Note 5) 262.6 278.6
Property, plant, and equipment, net 1,858.3 1,811.9
Operating lease right-of-use assets 100.2 102.7
Goodwill 1,951.7 1,768.6
Other intangible assets, net 1,161.1 1,128.2
Deferred income taxes 929.4 1,138.1
Other assets (Note 2) 633.6 730.2
Total assets 14,144.4 13,697.2
Current liabilities    
Accounts payable 199.7 227.5
Accrued and other liabilities (Note 2) 1,352.1 1,561.7
Operating lease liabilities 24.9 24.5
Total current liabilities 1,576.7 1,813.7
Long-term debt 598.8 598.3
Operating lease liabilities 80.8 82.6
Uncertain tax positions 580.3 502.7
Other liabilities 346.3 362.3
Total liabilities 3,182.9 3,359.6
Commitments and contingencies (Note 12)
Stockholders' equity    
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding 0.0 0.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 662.3 and 658.7 shares issued, and 575.6 and 580.7 shares outstanding, respectively 662.3 658.7
Additional paid-in capital 3,057.6 2,768.4
Retained earnings 15,170.6 14,240.5
Accumulated other comprehensive loss (Note 13) (220.2) (238.3)
Treasury stock, at cost, 86.7 and 78.0 shares, respectively (7,809.2) (7,091.7)
Total Edwards Lifesciences Corporation stockholders' equity 10,861.1 10,337.6
Noncontrolling interest 100.4 0.0
Total stockholders' equity 10,961.5 10,337.6
Total liabilities and equity $ 14,144.4 $ 13,697.2